GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (LTS:0RKL) » Definitions » Capital Expenditure

Xvivo Perfusion AB (LTS:0RKL) Capital Expenditure : kr0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Xvivo Perfusion AB Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Xvivo Perfusion AB's cash flow for capital expenditures for the three months ended in Sep. 2024 was kr0.0 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Sep. 2024 was kr0.00 Mil.

Xvivo Perfusion AB Capital Expenditure Historical Data

The historical data trend for Xvivo Perfusion AB's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xvivo Perfusion AB Capital Expenditure Chart

Xvivo Perfusion AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only -83.69 -64.68 -94.07 -130.95 -143.94

Xvivo Perfusion AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Xvivo Perfusion AB Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xvivo Perfusion AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (LTS:0RKL) » Definitions » Capital Expenditure
Comparable Companies
OSTO:MCAP OSTO:CEVI OSTO:BACTI B OSTO:BICO OSTO:SEDANA OSTO:CRAD B OSTO:BRAIN OSTO:MNTC OSTO:SEZI OSTO:INTEG B ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
XVIPF:USA XVIVO:Sweden XVIVOs:UK 3XV:Germany
Address
Gemenskapens gata 9, Molndal, SWE, SE-431 53
Website
https://www.xvivoperfusion.com
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.

Xvivo Perfusion AB Headlines

No Headlines